Publikationen in Zusammenarbeit mit Forschern von Centro de Investigación Médica Aplicada (108)

2024

  1. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

    Blood, Vol. 141, Núm. 9, pp. 1047-1059

  2. Chronic docosahexaenoic acid supplementation improves metabolic plasticity in subcutaneous adipose tissue of aged obese female mice

    Journal of Nutritional Biochemistry, Vol. 111

  3. Differential remodeling of subcutaneous white and interscapular brown adipose tissue by long-term exercise training in aged obese female mice

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 2, pp. 451-465

  4. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  5. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  6. Regulation and role of the PP2A-B56 holoenzyme family in cancer

    Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1878, Núm. 5

  7. Set Protein Is Involved in FLT3 Membrane Trafficking

    Cancers, Vol. 15, Núm. 8

  8. Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

    Blood, Vol. 141, Núm. 21, pp. 2615-2628

  9. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

    Journal for immunotherapy of cancer, Vol. 11, Núm. 2

2022

  1. DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

    Cancers, Vol. 14, Núm. 9

  2. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

  3. SLU7: A New Hub of Gene Expression Regulation—From Epigenetics to Protein Stability in Health and Disease

    International Journal of Molecular Sciences, Vol. 23, Núm. 21

  4. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  2. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

  3. Epigenetic biomarkers for the diagnosis and treatment of liver disease

    Cancers, Vol. 13, Núm. 6, pp. 1-15

  4. Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis

    Gut, Vol. 70, Núm. 2, pp. 388-400

  5. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

  6. The pd-1/pd-l1 checkpoint in normal germinal centers and diffuse large b-cell lymphomas

    Cancers, Vol. 13, Núm. 18